Overview
- 30 inspections across 28 sites are on record.
- 168 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2020-03-20.
At a glance
Inspections
30
Sites
28
Observations
168
Career since
May 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| 3M Company | 20 Mar 2020 | Human Drugs | View 483 → |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 Mar 2020 | Human Drugs | On file |
| Hospira, Inc. | 17 Jan 2020 | Human Drugs | View 483 → |
| Lifecore Biomedical, LLC | 22 Nov 2019 | Human Drugs | |
| Shalem Products Inc | 24 Sep 2019 | Human Drugs | View 483 → |
Sites inspected
3M CompanySaint Paul, United States1 insp.
Takeda Pharmaceuticals U.S.A., Inc.Brooklyn Park, United States1 insp.
Hospira, Inc.Mcpherson, United States1 insp.
Lifecore Biomedical, LLCChaska, United States1 insp.
Shalem Products IncAngora, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Ross J Grigsby10 shared
James K Ireland4 shared
Courtney R Ingalsbe3 shared
Matthew B Casale2 shared
Bo Chi1 shared
Simone E Pitts1 shared
Jazmine N Still1 shared
Yoon K Oh1 shared
Anthony J Ladner1 shared
Sarah E Rhoades1 shared
Full investigator report
Get the verbatim findings behind Scott A Golladay's 168 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site